Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
McKinsey
Teva
Mallinckrodt
Covington
Cipla
Johnson and Johnson
Fuji

Generated: February 16, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062662

« Back to Dashboard

NDA 062662 describes TAZICEF, which is a drug marketed by Hospira and is included in two NDAs. It is available from one supplier. Additional details are available on the TAZICEF profile page.

The generic ingredient in TAZICEF is ceftazidime. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 062662
Tradename:TAZICEF
Applicant:Hospira
Ingredient:ceftazidime
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 062662
Medical Subject Heading (MeSH) Categories for 062662
Suppliers and Packaging for NDA: 062662
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAZICEF ceftazidime INJECTABLE;INJECTION 062662 ANDA Hospira, Inc. 0409-5082 0409-5082-16 25 VIAL in 1 TRAY (0409-5082-16) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL
TAZICEF ceftazidime INJECTABLE;INJECTION 062662 ANDA Hospira, Inc. 0409-5084 0409-5084-11 10 VIAL in 1 TRAY (0409-5084-11) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength500MG/VIAL
Approval Date:Mar 6, 1986TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL
Approval Date:Mar 6, 1986TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/VIAL
Approval Date:Mar 6, 1986TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Accenture
UBS
Johnson and Johnson
Mallinckrodt
Cipla
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.